CPT code 87230 describes a laboratory cytotoxicity assay used to detect toxins or poisons produced by specific organisms (for example, Clostridium difficile) using cell or tissue culture. This test is clinically important because it directly identifies biologically active toxin, which can confirm toxin-mediated disease and guide clinical management. Nationally, accurate coding and coverage for toxin assays affect laboratory workflow, hospital diagnostic pathways, and public health surveillance.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for cytotoxicity-based toxin testing, typical sites of service, and the common modifiers associated with lab billing. The publication outlines what to expect in payer coverage policies, coding considerations for laboratory reporting, and benchmark topics relevant to utilization and reimbursement practice.

The report also summarizes common operational implications for laboratories that perform culture-based toxin assays, including equipment and staffing needs inherent to cell/tissue culture testing. Data not available in the input will be noted where applicable. The focus is national policy and billing context rather than state-level specifics.